Use of sulforaphane in COVID-19: Clinical trials are needed

Chia Siang Kow; Dinesh Sangarran Ramachandram; Syed Shahzad Hasan

doi:10.1016/j.molimm.2022.03.001

Use of sulforaphane in COVID-19: Clinical trials are needed

Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan

Research output: Contribution to journal › Letter › peer-review

9 Citations (Scopus)

Abstract

We read with interest the narrative review authored by Kiser et al. (2021), which discussed extensively the antioxidant effect and anti-inflammatory effect of sulforaphane, a dietary supplement found in high amounts in cruciferous vegetables that is orally accessible and well-tolerated. Notably, in their review, the authors also discussed the potential use of sulforaphane in patients with coronavirus disease 2019 (COVID-19). Sulforaphane mediates the inhibitory effect on NLRP3 inflammasome activation and we believe that this could be the main mechanism where sulforaphane is useful for patients with COVID-19.

Original language	English
Pages (from-to)	78-79
Number of pages	2
Journal	Molecular Immunology
Volume	145
Early online date	15 Mar 2022
DOIs	https://doi.org/10.1016/j.molimm.2022.03.001
Publication status	Published - 1 May 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.molimm.2022.03.001Licence: Unspecified

Cite this

@article{5ab4433af6634b67b845a749ea82c6ac,

title = "Use of sulforaphane in COVID-19: Clinical trials are needed",

abstract = "We read with interest the narrative review authored by Kiser et al. (2021), which discussed extensively the antioxidant effect and anti-inflammatory effect of sulforaphane, a dietary supplement found in high amounts in cruciferous vegetables that is orally accessible and well-tolerated. Notably, in their review, the authors also discussed the potential use of sulforaphane in patients with coronavirus disease 2019 (COVID-19). Sulforaphane mediates the inhibitory effect on NLRP3 inflammasome activation and we believe that this could be the main mechanism where sulforaphane is useful for patients with COVID-19.",

keywords = "sulforaphane, COVID-19, clinical trial",

author = "Kow, {Chia Siang} and Ramachandram, {Dinesh Sangarran} and Hasan, {Syed Shahzad}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = may,

day = "1",

doi = "10.1016/j.molimm.2022.03.001",

language = "English",

volume = "145",

pages = "78--79",

journal = "Molecular Immunology",

issn = "0161-5890",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Use of sulforaphane in COVID-19

T2 - Clinical trials are needed

AU - Kow, Chia Siang

AU - Ramachandram, Dinesh Sangarran

AU - Hasan, Syed Shahzad

PY - 2022/5/1

Y1 - 2022/5/1

N2 - We read with interest the narrative review authored by Kiser et al. (2021), which discussed extensively the antioxidant effect and anti-inflammatory effect of sulforaphane, a dietary supplement found in high amounts in cruciferous vegetables that is orally accessible and well-tolerated. Notably, in their review, the authors also discussed the potential use of sulforaphane in patients with coronavirus disease 2019 (COVID-19). Sulforaphane mediates the inhibitory effect on NLRP3 inflammasome activation and we believe that this could be the main mechanism where sulforaphane is useful for patients with COVID-19.

AB - We read with interest the narrative review authored by Kiser et al. (2021), which discussed extensively the antioxidant effect and anti-inflammatory effect of sulforaphane, a dietary supplement found in high amounts in cruciferous vegetables that is orally accessible and well-tolerated. Notably, in their review, the authors also discussed the potential use of sulforaphane in patients with coronavirus disease 2019 (COVID-19). Sulforaphane mediates the inhibitory effect on NLRP3 inflammasome activation and we believe that this could be the main mechanism where sulforaphane is useful for patients with COVID-19.

KW - sulforaphane

KW - COVID-19

KW - clinical trial

UR - http://www.scopus.com/inward/record.url?scp=85126550548&partnerID=8YFLogxK

U2 - 10.1016/j.molimm.2022.03.001

DO - 10.1016/j.molimm.2022.03.001

M3 - Letter

AN - SCOPUS:85126550548

SN - 0161-5890

VL - 145

SP - 78

EP - 79

JO - Molecular Immunology

JF - Molecular Immunology

ER -

Use of sulforaphane in COVID-19: Clinical trials are needed

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this